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Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease with a high
prevalence of hypertension. NZBWF1 (SLE-Hyp) mice develop hypertension
that can be prevented by modulating T cells. The peptide N-acetyl-seryl-aspar-
tyl-lysyl-proline (Ac-SDKP) decreases renal damage and improves renal func-
tion in a model of SLE without hypertension (MRL/lpr). However, it is not
known whether Ac-SDKP prevents hypertension in NZBWF1 mice. We
hypothesized that in SLE-Hyp, Ac-SDKP prevents hypertension and renal
damage by modulating T cells. Animals were divided into four groups: (1)
control + vehicle, (2) control + Ac-SDKP, (3) SLE + vehicle, and (4)
SLE + Ac-SDKP. Systolic blood pressure (SBP), albuminuria, renal fibrosis,
and T-cell phenotype were analyzed. SBP was higher in SLE compared to con-
trol mice and was not decreased by Ac-SDKP treatment. Half of SLE mice
developed an acute and severe form of hypertension accompanied by albu-
minuria followed by death. Ac-SDKP delayed development of severe hyperten-
sion, albuminuria, and early mortality, but this delay did not reach statistical
significance. Ac-SDKP prevented glomerulosclerosis, but not interstitial fibro-
sis in SLE-Hyp mice. SLE-Hyp mice showed a decrease in helper and cyto-
toxic T cells as well as an increase in double negative lymphocytes and T
helper 17 cells, but these cells were unaffected by Ac-SDKP. In conclusion,
Ac-SDKP prevents kidney damage, without affecting blood pressure in an SLE
animal model. However, during the acute relapse of SLE, Ac-SDKP might also
delay the manifestation of an acute and severe form of hypertension leading
to early mortality. Ac-SDKP is a potential tool to treat renal damage in SLE-
Hyp mice.
Introduction
Systemic lupus erythematosus (SLE) is a severe autoim-
mune disease of unknown origin, the pathogenesis of which
is incompletely understood. SLE has an unpredictable
course and a wide spectrum of disease manifestations with
remissions and relapses occurring over time. Hypertension
is the major risk factor for the progression of renal, vascu-
lar, and heart disease. Individuals with SLE develop hyper-
tension (Al-Herz et al. 2003) and are at an alarmingly high
risk for stroke, myocardial infarction, atherosclerosis, and
renal disease (Manzi et al. 1997; Rahman et al. 2000; Bruce
2005; Ryan and McLemore 2007). Additionally, hematolog-
ical abnormalities such as anemia, leucopenia, and lym-
phopenia are extremely common at the time of diagnosis
and during the follow-up course in SLE population (Aleem
et al. 2014). Despite the severity of the disease, which often
starts in the late childhood or adolescence and predomi-
nantly affects females in their reproductive years, treatment
options are scarce and include immunosuppressive drugs,
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steroids, and monoclonal antibodies targeting B cells and
B-cell activating factor. A hallmark of the disease is the
deposition of immune complexes in the tissues resulting in
inflammation induction (Ohl and Tenbrock 2015). Effec-
tor/memory CD4+ helper T cells (Th) regulate the immune
response by releasing of both proinflammatory and anti-
inflammatory cytokines. Based on effector function, Th
cells are classified in two subsets: Th1 cells that release
proinflammatory cytokines including interferon-gamma
(IFN-c), and Th2 cells that release interleukin (IL)-4 that
counteracts the IFN-c effects. Th17 cells release a unique
IL-17 cytokine involved in many autoimmune diseases,
including SLE (Crispin and Tsokos 2009). By contrast,
FoxP3+ regulatory T cells (Tregs) are responsible for main-
taining self-tolerance by suppressing autoreactive lympho-
cytes. Alterations of T-cell subtypes toward Th1 and Th17
phenotypes are thought to e important in autoimmune dis-
ease development. Female NZBWF1 (SLE-Hyp) mice are
the oldest classical model of SLE generated by the F1 hybrid
between New Zealand Black (NZB) and New Zealand
White (NZW) strains. Both NZB and NZW display limited
autoimmunity, whereas NZBWF1 hybrids develop a severe
phenotype comparable to that of lupus patients (The-
ofilopoulos and Dixon 1985). These lupus-like phenotypes
include lymphadenopathy, splenomegaly, elevated serum
antinuclear autoantibodies, and immunocomplex-
mediated glomerulonephritis that becomes apparent at 20–
24 weeks of age leading to kidney failure and death at 40–
48 weeks of age (Theofilopoulos and Dixon 1985). More-
over, female SLE-Hyp mice develop nonsalt-sensitive
hypertension (Mathis et al. 2011) and endothelial dysfunc-
tion at 34–36 weeks of age (Ryan and McLemore 2007).
High blood pressure and albuminuria in NZBWF1 mice
can be prevented by immunoregulatory drugs, such as
etanercept (tumor necrosis factor-alpha [TNF-a] antago-
nist) (Venegas-Pont et al. 2010), hydroxychloroquine
(Gomez-Guzman et al. 2014) or anti-CD20 antibodies
(Mathis et al. 2014), indicating that hypertension develop-
ment in this particular model depends on an inflammatory
immune mechanism.
N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a nat-
urally occurring tetrapeptide present in plasma, urine, and
several tissues including the heart and kidney (Cavasin
et al. 2007). Previously, we reported that Ac-SDKP exerts
anti-inflammatory as well as immunoregulatory properties,
and prevents hypertensive end-organ damage in addition
to autoimmune myocarditis and SLE (Peng et al. 2001;
Rhaleb et al. 2001; Omata et al. 2006; Liao et al. 2010;
Nakagawa et al. 2012; Gonzalez et al. 2014). Indeed, we
and others have reported that in MRL/lpr mice, a model of
SLE that differs from female NZBWF1, Ac-SDKP treatment
decreased lupus nephritis, renal inflammation, and fibrosis
(Omata et al. 2006; Liao et al. 2015). However, in these
previous studies, we could not study whether Ac-SDKP
prevents hypertension in SLE because the MRL/lpr model
develops lupus nephritis without hypertension. Ac-SDKP
was initially described as a physiological inhibitor of
hematopoietic stem cell proliferation (Lenfant et al. 1989).
Ac-SDKP is mainly hydrolyzed by angiotensin-converting
enzyme (ACE) (Azizi et al. 1997) and it has been suggested
that chronic accumulation of Ac-SDKP in plasma during
ACE inhibition could participate in the alterations of
hematopoiesis observed with ACE inhibitor treatment
(Comte et al. 1997). Therefore, abnormalities in hemato-
poiesis such as anemia and leucopenia which are common
in SLE, could be aggravated by Ac-SDKP. Because hyper-
tension development in SLE-Hyp mice is caused particu-
larly by autoimmune mechanisms, we hypothesized that
Ac-SDKP prevents development of autoimmune-mediated
kidney damage and hypertension without causing the
adverse effects. Moreover, we hypothesized that the benefi-
cial effects of Ac-SDKP are mediated by the inhibition of
T-cell differentiation.
Methods
Experimental animals
Female NZBWF1 (SLE-Hyp) and NZW (control) mice
were obtained from Jackson Laboratories (Bar Harbor,
ME). Animals were housed in an air-conditioned room
with a 1212-h light-dark cycle and given standard rodent
chow (0.4% sodium) with tap water. Animals were
allowed 7 days to adjust to their new environment. All
protocols were approved by the Institutional Animal Care
and Use Committee (IACUC) of Henry Ford Hospital.
Before all surgical procedures, butorphanol (2 mg/kg sc)
was used to induce analgesia and pentobarbital sodium
(50 mg/kg ip) was used for anesthesia.
Experimental protocols
Protocol 1 – study of the Ac-SDKP effects on blood
pressure, mortality, and renal damage in SLE
Female SLE-Hyp mice and NZW (control) mice at
24–38 weeks of age were treated either with 0.9% sodium
chloride containing 0.01 N acetic acid vehicle alone or with
800 lg/kg per day Ac-SDKP. The rats were divided into four
groups: (1) control + vehicle (Ctl + Veh, n = 6), (2)
control + Ac-SDKP (Ctl + Ac-SDKP, n = 6), (3) SLE-
Hyp + vehicle (SLE + Veh, n = 10), and (4) SLE-
Hyp + Ac-SDKP (SLE + Ac-SDKP, n = 10). Ac-SDKP was
infused subcutaneously at a dosage of 800 lg/kg per day via
an osmotic minipump (Alzet, Cupertino, CA) as described
previously (Liao et al. 2015). Systolic blood pressure (SBP)
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was monitored by tail cuff measurements, whereas urinary
albumin excretion was analyzed weekly by ELISA. At
38 weeks of age, animals were anesthetized with pentobarbi-
tal, killed, then plasma and organs were collected.
Protocol 2 – study of hematological parameters
and T-cell phenotypes
Female SLE-Hyp and control mice were divided into four
groups as described in protocol 1. Ac-SDKP was infused
subcutaneously at a higher dosage of 2400 lg/kg per day
via osmotic minipump from 20 to 35 weeks of age. We
monitored body weight and performed standard hemato-
logic studies at 32–33 weeks of age. Flow cytometry
analysis was performed at 34–35 weeks of age to evaluate
T-cell phenotype.
Systolic blood pressure
SBP was measured in conscious mice using a noninvasive
computerized tail cuff system (MC-4000, from Hatteras
Instruments, Cary, NC) as described previously (Yang
et al. 1999). Mice were trained for 3 days by measuring
SBP daily, after which SBP was measured and recorded
weekly. The results are expressed as the mean SBP  s-
tandard error and also as % of incidence of severe hyper-
tension (defined as SBP >140 mmHg).
Urinary albumin excretion
The animals were placed in metabolic cages, and the
urine was collected for 24 h. The urine samples were cen-
trifuged twice at 13,400g at 4°C and the supernatant was
filtered using a 0.22-lm low-protein retention filters.
Albumin concentration was measured by ELISA using a
commercially available kit (GenWay Biotech., San Diego,
CA). The 24-h albumin excretion was calculated by multi-
plying the urine albumin concentration by the urine vol-
ume and expressed as lg/24 h. The incidence of
albuminuria (defined as a 24-h albumin excretion rate
>50 lg) was monitored weekly.
Glomerular matrix analysis
Paraffin-embedded tissue sections (4 lm) were stained
with periodic acid Schiff (PAS). At least 35 glomeruli
within randomly chosen fields of renal cortex were imaged
at 4009 magnification. A dark pink color was considered
positive staining representing the extracellular matrix.
Glomerular matrix was analyzed by computerized image
analysis system (Microsuite Biological imaging software,
Olympus America, Center Valley, PA) and positive staining
was expressed as the percentage of glomerular area. All of
the images shown in this study were captured and analyzed
using the same imaging system. All measurements and
analyses were performed in a blind fashion.
Collagen deposition
Picrosirius red staining was used to quantify renal inter-
stitial collagen deposition (Nakagawa et al. 2012; Liao
et al. 2015). Randomly chosen fields within corti-
comedullary junctions were imaged at 2009 magnifica-
tion. The interstitial collagen fraction was calculated as
the ratio of the collagen-positive area to the imaging area.
Flow cytometry analysis
Heparinized blood was collected from tail vein, and red
blood cells (RBCs) were lysed using Ammonium-Chloride-
Potassium (ACK) buffer. LIVE/DEAD Aqua dead cell stain-
ing kit (Life Technologies, Carlsbad, CA) was used to
exclude dead cells. Cells were fixed and permeabilized using
a commercially available buffer (eBioscience, San Diego,
CA) and then Fc receptors blocked with an anti-CD16/32
antibody. Cells were stained with fluorescein isothiocyanate
(FITC) anti-mouse CD4 (Biolegend, San Diego, CA, clone
RM4-4), alexa fluor 700 anti-mouse CD8 (Biolegend, clone
53-6.7), and phycoerythrin (PE) anti-mouse/human FoxP3
(Biolegend, clone 150D) for 20 min. For intracellular cyto-
kine staining, blood cells were stimulated with 50 ng/mL
Phorbol 12-Myristate 13 Acetate (Sigma Aldrich, St. Louis,
MO), 1 lg/mL ionomycin (Sigma Aldrich), and 5 lg/mL
brefeldin A (Sigma Aldrich) for 4 h at 37°C. Cells were
fixed, permeabilized and stained with FITC anti-mouse
CD4, brilliant violet anti-mouse IFN-c (Biolegend, clone
XM 61.2), PE, anti-mouse IL-4 (Biolegend, clone 11B11),
and alexa fluor 647, anti-mouse IL-17 (Biolegend,
clone TC11-18H10.1) antibodies to identify CD4+ IFN-c+
Th1 cells, CD4+ IL-4+ Th2 cells, and CD4+ IL-17+ Th17
cells. At least 20,000 cells were analyzed using a BD Fortessa
flow cytometer (BD Biosciences, San Jose, CA). Flow
cytometry data were analyzed using FlowJo software (BD
Biosciences).
Hematological studies
Heparinized blood was collected from tail vein. The RBC
and white blood cell (WBC) counts were determined
using a hemocytometer with a Neubauer chamber. For the
WBC count, blood samples were resuspended in 2% acetic
acid and incubated for 1 min to lyse the RBC. For the dif-
ferential WBC count, we prepared blood smears that were
stained with Hema-3 staining kit (Sigma Aldrich). Cells
were quantified under a Nikkon Eclipse E600 microscope
(Nikon, Tokyo, Japan). Neutrophil, lymphocyte, and
ª 2017 Henry Ford Health System. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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monocyte cell lineages were identified by morphology and
differential staining patterns. The absolute cell numbers
were derived by multiplying the total WBC count by the
percent of neutrophils, lymphocytes, or monocytes.
Data analysis
All data are expressed as means  SE. Statistical signifi-
cance of the data was calculated by Kruskall–Wallis test
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Figure 1. SBP measurements by tail cuff in (A) nonlupus mice treated with vehicle alone (control + vehicle, n = 6), (B) nonlupus mice treated
with Ac-SDKP (control + Ac-SDKP, n = 6), (C) lupos mice treated with vehicle (SLE + vehicle, n = 10), and (D) lupus mice treated with Ac-SDKP
(SLE + Ac-SDKP, n = 10). Blood pressure was monitored weekly from 25 to 38 weeks of age. Vehicle or Ac-SDKP (800 lg/kg per day) were
infused via osmotic minipump from the age of 25 weeks. The recording of each individual mouse SBP is represented in different colors and the
mouse ID number is shown at the figure inset. Some of the SLE mice developed a very aggressive and acute form of hypertension (SBP
>140 mmHg) that was followed by death. The time of the manifestation of the acute hypertension manifestation in vehicle-treated SLE-Hyp
mice occurred from 27 to 29 weeks of age, whereas in Ac-SDKP-treated animals, it occurred between 32 and 35 weeks of age. SBP, systolic
blood pressure; Ac-SDKP, N-acetyl-seryl-aspartyl-lysyl-proline; SLE, systemic lupus erythematosus.
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followed by a Wilcoxon two-sample analysis. A value of
P < 0.05 was considered significant.
Results
Effects of Ac-SDKP on SLE disease severity
We observed a remarkable variability in both the manifes-
tation time and the SP-defined disease severity among the
animals (Fig. 1). The SBP raw data values shown in Fig-
ure 1 were averaged and analyzed. When we compared
the SBP averages among the groups, we observed a signif-
icantly higher SBP in SLE + veh mice compared to the
nonlupus control group, and this increase was not pre-
vented by Ac-SDKP (Fig. 2A). In Figure 1C and B, we
also observed that some SLE mice developed a severe and
acute form of hypertension (SBP >140 mmHg) that was
followed by death. Animals found dead contained an
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Figure 2. SBP was monitored by tail cuff method in control and SLE mice treated either with vehicle or Ac-SDKP (800 lg/kg per day) from 24 to
38 weeks of age. The results are expressed as (A) SBP mean  standard error and (B) incidence of severe hypertension (defined as SBP >140 mmHg).
(C) Effect of Ac-SDKP and vehicle on survival rate in control and SLE mice from 25 to 38 weeks of age. The mortality and incidence of severe
hypertension tended to be delayed in Ac-SDKP-treated SLE mice. *P < 0.001 SLE + veh versus control + veh and **P < 0.07 SLE + Ac-SDKP versus
SLE + veh. SBP, systolic blood pressure; SLE, systemic lupus erythematosus; Ac-SDKP, N-acetyl-seryl-aspartyl-lysyl-proline.
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excessive amount of fluid in the abdominal cavity,
whereas no bleeding in brain, chest, or abdominal cavity
was found. Ac-SDKP tended to delay the manifestation of
severe hypertension in SLE-Hyp by 6 weeks of age
(Fig. 2B). However, these differences did not reach
statistical significance due to the great variability observed
in this model. The mortality rate in SLE-Hyp mice was
50% at the end of the experimental protocol, whereas all
of the animals in the control group survived. Although
Ac-SDKP treatment did not reduce the mortality rate, it
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Figure 3. Albumin excretion rate measurements by ELISA in (A) control + vehicle (n = 6), (B) control + Ac-SDKP (n = 6), (C) SLE + vehicle
(n = 10), and (D) SLE + Ac-SDKP (n = 10). The albumin excretion rate was monitored weekly from 25 to 38 weeks of age. Vehicle or Ac-SDKP
(800 lg/kg per day) were infused via osmotic minipump from the age of 24 weeks. The recording of each individual mouse albumin excretion
is represented in different colors, and the mouse ID number is shown in the figure inset. Some animals developed flares and remissions,
whereas others did not show any indication of albuminuria. The time frame of albuminuria development in the SLE + veh group varied from 27
to 37 weeks of age. Ac-SDKP tended to delay the development of massive albuminuria and death in SLE-Hyp. Ac-SDKP, N-acetyl-seryl-aspartyl-
lysyl-proline; SLE, systemic lupus erythematosus.
2017 | Vol. 5 | Iss. 2 | e13084
Page 6
ª 2017 Henry Ford Health System. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Ac-SDKP in SLE Hypertension P. Nakagawa et al.
tended to delay death in these animals (Fig. 2C). In con-
trol mice, Ac-SDKP had no effect on the mortality rate.
During the albuminuria follow-up, some animals devel-
oped flares and remissions, whereas other animals showed
no indication of SLE activity (Fig. 3). The time frame of
albuminuria development in the SLE + veh group varied
from 27 to 37 weeks of age. Seventy percent of SLE-Hyp
mice developed severe albuminuria (defined as a 24-h
albumin excretion rate >50 lg), whereas no albuminuria
was detected in control mice (Fig. 3). Ac-SDKP tended to
delay the development of severe albuminuria in SLE-Hyp
(Fig. 4).
Histological analysis of the kidneys revealed that in
SLE-Hyp mice, Ac-SDKP decreased glomerulosclerosis
(SLE + veh: 11.5  0.5 vs. SLE + Ac-SDKP: 7.8  0.5%
of total glomerular area; Fig. 5) but not interstitial
collagen deposition (SLE + veh: 4.6  0.5 vs. SLE + Ac-
SDKP: 4.7  0.5% of area; Table 1). No difference in
kidney weight when corrected by body weight was
observed between control and SLE-Hyp mice (Ctl + veh:
5.8  0.1 vs. SLE + veh: 5.6  0.2; Table 1) and Ac-
SDKP had no effects on kidney weight. Plasma anti--
dsDNA IgG autoantibody titer, an index of disease
activity, was measured at 38 weeks of age. We observed an
important dispersion in anti-dsDNA IgG antibody levels in
control and SLE-Hyp mice. SLE-Hyp mice had higher anti-
dsDNA IgG levels compared to the control animals
(SLE + veh: 137.5  68.9 vs. Ctl + veh: 13.1  2.8 kU/
mL, P = 0.076), but this difference was not statistically sig-
nificant due to the high standard deviation. In SLE-Hyp
mice, Ac-SDKP treatment did not alter anti-dsDNA anti-
body levels (SLE + veh: 137.5  68.9 vs. SLE + Ac-SDKP:
82.6  25.3 kU/mL), nor body weight (SLE + veh:
41.3  0.9 vs. SLE + Ac-SDKP: 39.7  1.5 g) (Table 1).
Flow cytometry analysis of T cells
As shown in Figure 6A, the percentage of T helper
(CD4+) and T cytotoxic (CD8+) lymphocytes was reduced
in SLE-Hyp mice in comparison to control mice. In con-
trast, the percentage of double negative CD4 CD8 lym-
phocytes (DN) were increased in SLE-Hyp mice
compared to the control animals. As shown in Figure 6B,
intracellular cytokine analysis of peripheral blood T helper
cells revealed an increase in the percentage of IFN-c-posi-
tive Th1 cells in SLE-Hyp mice compared to control
mice. The percentages of both IL-17-positive Th17 cells
and FoxP3-positive Treg cells were also increased in SLE-
Hyp mice compared to control mice. Ac-SDKP did not
alter the percentage of peripheral blood T helper, cyto-
toxic T cells, or DN cells in control nor SLE-Hyp
(Fig. 6A). Intracellular flow cytometry analysis indicates
that in SLE-Hyp mice, Ac-SDKP does not decrease the
percentage of Th1 cells, Th17 cells, nor Tregs (Fig. 6B).
Hematologic parameters
As shown in Figure 7A, we did not observe differences in
RBC count between control and SLE-Hyp mice. However,
the leukocyte count was significantly decreased in SLE-
Hyp mice compared to control mice (Fig. 7B). The differ-
ential leukocyte count in peripheral blood indicated that
the leucopenia was caused by a severe decrease in lym-
phocytes, whereas differential counts of other WBCs such
as neutrophils and monocytes, were not altered in SLE-
Hyp mice (Fig. 7C). Ac-SDKP did not cause anemia in
control mice or in SLE-Hyp mice (Fig. 7A). Ac-SDKP did
not affect peripheral blood leukocyte counts in control
mice or in SLE-Hyp mice (Fig. 7B and C).
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Discussion
Previously, we and others reported that Ac-SDKP pre-
vents inflammation, fibrosis, lupus nephritis, and
improves renal function in lupus-prone MRL/lpr mice
(Tan et al. 2012; Liao et al. 2015). MRL/lpr mice carry a
genetic mutation in the lymphoproliferative (lpr) gene
that encodes Fas ligand, and mice with inactive Fas ligand
develop an aggressive form of lupus nephritis. However,
MRL/lpr mice do not develop hypertension; thus, our
previous study was limited on studying the effects of Ac-
SDKP on lupus nephritis, but not on the development of
lupus-associated hypertension development. Unlike MRL/
lpr mice, female NZBWF1 (SLE-Hyp) mice not only
develop nephritis, but also hypertension. The etiology of
the disease in SLE-Hyp does not depend on a single
genetic mutation. Here, we used the SLE-Hyp as a model
of hypertension related to SLE to test the effect of Ac-
SDKP on blood pressure and renal damage in SLE. From
the beginning of the experimental protocol (25 weeks of
age), SLE-Hyp mice exhibited a significantly higher blood
pressure, compared to control NZW mice. As shown in
Figures 1, 3, we also observed that half of the animals in
SLE-Hyp mice developed acute flares with a fatal form of
hypertension, massive albuminuria, and died immediately
afterwards. The cause of death in these animals is likely
renal and heart failure because the animals contained a
large amount of fluids in the abdominal cavity, indicating
ascites, whereas no hemorrhages or abnormalities were
found in the chest, abdomen, or brain. Development of
these fatal manifestations did not occur simultaneously in
all animals, but on average, it occurred earlier than
expected because the reported average lifespan for
NZBWF1 is 35 weeks (245 days) (Dubois et al. 1966).
We do not know the cause of these discrepancies, but we
speculate that environmental factors such as diet, micro-
biome, environment temperature, and exposure to stres-
sors could influence the lifespan of these animals. As
shown in Figure 2B and C, the manifestation time of sev-
ere hypertension and mortality in vehicle-treated SLE-
Hyp mice occurred from 27 to 29 weeks of age, whereas
in Ac-SDKP-treated animals, it occurred between 32 and
35 weeks of age. Animals that survived were killed at
38 weeks and glomerular matrix deposition was measured
(Fig. 5). There was a decrease in glomerular matrix depo-
sition in Ac-SDKP-treated group indicating that Ac-SDKP
could be delaying the progression of kidney injury. Inter-
estingly, SLE-Hyp mice had a similar degree of glomeru-
losclerosis compared to control animals. We attribute
these unexpected results to two factors. First, the animals
with the highest degree of renal damage developed fatal
renal disease and died before the end of the protocol.
Thus, we only measured glomerular matrix deposition in
the survivors that exhibited mild disease. Second, the con-
trol NZW mice do also develop a mild and limited SLE-
like disease during more advanced age. Thus, we expected
some degree of glomerulosclerosis in the control group.
Nevertheless, we observed a decrease in the degree of
glomerular damage in Ac-SDKP-treated animals, and this
is consistent with many previous studies (Peng et al.
2001; Rhaleb et al. 2011; Liao et al. 2015; Worou et al.
Control + vehicleA
B
Control + Ac-SDKP
SLE + vehicle SLE + Ac-SDKP
Co
ntr
ol+
ve
hic
le
Co
ntr
ol+
Ac
-S
DK
P
SL
E+
ve
hic
le
SL
E+
Ac
-S
DK
P
0
5
10
15
G
lo
m
er
ul
ar
 m
at
rix
(%
 o
f g
lo
m
er
ul
ar
 a
re
a)
P = 0.002P = 0.316
Figure 5. (A) Representative pictures of glomerular matrix
deposition expressed as percentage of total glomerular area and
measured by periodic acid Schiff staining in mice that survived at
38 weeks. (B) Quantitative data on glomerular matrix deposition. In
SLE-Hyp, Ac-SDKP prevented glomerular matrix deposition
indicating protection from renal damage. In control mice, Ac-SDKP
also tended to decrease glomerulosclerosis, but it did not reach
statistical significance. SLE, systemic lupus erythematosus; Ac-SDKP,
N-acetyl-seryl-aspartyl-lysyl-proline.
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2015). Although Ac-SDKP tended to delay the incidence
of these fatal manifestations. The mean SBP value
between the vehicle-treated SLE-Hyp mice and Ac-SDKP-
treated mice was similar (Fig. 2A). One of the limitations
of this study is the lack of renal functional analysis. In
the nonhypertensive mice, Ac-SDKP prevented the decline
of renal function. Thus, future studies will needed to
determine whether Ac-SDKP improves renal function in
SLE-Hyp. It is not surprising that Ac-SDKP does not
decrease blood pressure in SLE because we previously
showed that in many models of hypertension, Ac-SDKP
decreased renal inflammation and fibrosis without
decreasing the blood pressure (Rhaleb et al. 2001; Gonza-
lez et al. 2014). Ryan et al. showed that the inflammatory
response is involved in SLE-associated hypertension devel-
opment (Mathis et al. 2014). Because Ac-SDKP is a
potent anti-inflammatory peptide, one might expect that
Ac-SDKP could prevent hypertension development in SLE
or other immune-mediated diseases. In this study, Ac-
SDKP decreased glomerular damage but without decreas-
ing blood pressure, indicating that hypertension in SLE is
does not result from glomerosclerosis. Petrin et al. (1993)
reported a dissociation between arterial blood pressure
and glomerulonephritis in SLE. Additionally, a lack of
association between arterial blood pressure and nephritis
in MRL/lpr mice [ref] supports the hypothesis that hyper-
tension occurs independently of nephritis in SLE. In SLE-
Hyp, we observed many alterations in the proportion of
T-cell subsets. As shown in Figure 6A, we observed that
in SLE-Hyp mice had lower proportions of CD4+ T
helper lymphocytes and CD8+ cytotoxic T lymphocytes,
whereas CD4 CD8- DN cells were augmented. Previous
reports showed an expansion of DN T cells in lupus
patients. DN T cells release IL-1b, IL-17, and IFN-c (Cris-
pin and Tsokos 2009), provide help to B cells, and con-
tribute to the abnormal autoantibody profile in lupus
patients (Shivakumar et al. 1989). Additionally, SLE-Hyp
mice showed an increased proinflammatory Th1 and
Th17 profile. Schmidt et al. (2015) and other investigators
demonstrated that neutralizing IFN-c attenuates disease
severity in SLE-Hyp and MRL/lpr mice, whereas the
Th17/IL-17 immune response is not involved in the
immunopathogenesis of lupus nephritis in MRL/lpr or
SLE-Hyp mice. The effects of IFN-c and IL-17 on
Table 1. Ac-SDKP effects on body weight, anti-dsDNA IgG, kidney weight, and interstitial collagen deposition in Ctl and SLE mice treated
with veh or Ac-SDKP (800 lg/kg per day).
Ctl + veh Ctl + Ac-SDKP SLE + Veh SLE + Ac-SDKP
Body weight (g) 33.2  1.0 32.5  0.9 41.3  0.91 39.7  1.5
Anti-dsDNA IgG (kU/mL) 13.1  2.8 93.4  31.1 137.5  68.9 82.6  25.3
Kidney weight (mg) 194  7 194  9 228  7 219  10
Kidney weight corrected by body weight (mg/g) 5.8  0.2 5.9  0.2 5.6  0.1 5.8  0.3
Interstitial collagen deposition (% of area) 4.2  0.5 4.0  0.5 4.6  0.4 4.7  0.5
Values are means  SE. Ac-SDKP, N-acetyl-seryl-aspartyl-lysyl-proline; Ctl, control; SLE, systemic lupus erythematosus; Veh, vehicle.
1P < 0.01 Ctl + veh versus SLE + veh.
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Figure 6. Flow cytometry analysis of peripheral blood cells sampled
at 32–33 weeks of age in control and SLE with hypertension mice
treated either with vehicle or Ac-SDKP (2400 lg/kg per day). (A)
Percentage of CD4-positive, CD8-positive, and double negative
lymphocytes. (B) Percentage of CD4-positive Th1, Th2, T17 T cells,
and Tregs. SLE, systemic lupus erythematosus; Ac-SDKP, N-acetyl-
seryl-aspartyl-lysyl-proline.
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hypertension development in SLE-Hyp mice remain
unknown. Defects in or lack of Tregs are thought to con-
tribute to SLE pathogenesis (Scheinecker et al. 2010).
Paradoxically, we observed that the percentage of periph-
eral blood FoxP3+ Tregs were increased in SLE-Hyp com-
pared to controls. It has been reported previously that
Tregs are suppressed in the spleen of SLE-Hyp mice, but
augmented in the lymph nodes and kidney of the same
animals (Ohl and Tenbrock 2015). Our study is the first
reporting Treg levels in the peripheral blood of SLE-Hyp
mice. We speculate that the abundant Tregs observed in
SLE-Hyp might display low or absent suppressive effects
as suggested by Ohl and Tenbrock (2015). Indeed, Zhou
et al. (2009) suggested that FoxP3 instability in Tregs leads
to pathogenic cells that release inflammatory cytokines. In
MRL/lpr mice, Ac-SDKP has been shown to decrease
many proinflammatory factors such as the complement
system activation (C5a), TNF-a, RANTES, monocyte
chemoattractant protein-5 (MCP-5), intercellular adhe-
sion molecule-1 (ICAM-1), and the proinflammatory
transcription factor NF-kB. Most of the anti-inflamma-
tory effects of Ac-SDKP are mainly mediated by its effects
on the innate immunity (macrophages) (Sharma et al.
2008). However, whether Ac-SDKP modulates T-cell phe-
notype in SLE-Hyp was still unknown. In this study we
hypothesized that by shifting the balance of T cells toward
an anti-inflammatory phenotype Ac-SDKP ameliorates
the severity of the disease and decreases blood pressure in
SLE. Contrary to our hypothesis, Ac-SDKP did not bal-
ance T cells toward an anti-inflammatory phenotype. We
speculate that drugs targeting the T-cell response and
IL-17 signaling could be beneficial not only to treat SLE,
but also to treat SLE hypertension. Ac-SDKP is suspected
to be responsible for the anemia caused by ACE inhibi-
tors (Abu-Alfa and Perazella 2002), and SLE is a disease
associated with hematological alterations such as anemia,
lymphopenia, and thrombocytopenia (Aleem et al. 2014).
Thus, a possible side effect of Ac-SDKP on hematopoietic
system could be expected in SLE. In SLE-Hyp mice, the
WBCs were dramatically decreased. Differential analysis
revealed a severe lymphopenia, whereas no alterations
were found in the numbers of neutrophils or monocytes.
Ac-SDKP did not correct these abnormalities, but did not
further decrease the lymphocyte counts nor cause anemia
in these animals, indicating Ac-SDKP could be used to
treat SLE without adverse effects.
We conclude that Ac-SDKP prevents renal damage in
SLE-Hyp mice, ameliorating fatal renal disease manifesta-
tions and delaying mortality, without causing or aggravat-
ing anemia and lymphopenia. However, Ac-SDKP fails to
reduce blood pressure and systemic T-cell phenotype. This
study supports our previous findings indicating that Ac-
SDKP could be a potential therapeutic tool for preventing
or treating renal damage in hypertension or other autoim-
mune diseases without affecting blood pressure.
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